We are advancing programs targeting BET bromodomains in oncology and other disorders with significant unmet medical need. Our lead product, ZEN-3694, a pan selective BET inhibitor, is advancing in clinical trials for treatment of metastatic prostate cancer.  A single agent study has been completed and a combination study with enzalutamide is ongoing.

In addition to Prostate cancer, we are evaluating other solid tumor cancers with a large unmet medical need, including breast cancers (ER+ and TNBC) and lung cancer.


Our development strategy is focused on targeting patient subsets with high unmet need and those that are most likely to benefit from therapy.  We have built a rich translational program, guided by pre-clinical evidence and biological rationale to implement patient pre-selection strategies into clinical trial designs. 

In addition to the ongoing clinical activities, we are also developing the next generation of selective BET inhibitors.